Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPO-100 in Advanced Solid Tumors
NCT04931823Phase 1Terminated
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Aug 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of albumin-bound docetaxel in solid tumor (6 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 4 weeks and Adverse Events up to 4 years. Started Mar 2021; status: terminated.
02
Drugs
albumin-bound docetaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04931823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931823.